###begin article-title 0
###xml 17 21 <span type="species:ncbi:10090">mice</span>
Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 80 87 80 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 356 363 356 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 324 328 <span type="species:ncbi:10090">mice</span>
###xml 552 556 <span type="species:ncbi:10090">mice</span>
###xml 713 717 <span type="species:ncbi:10090">mice</span>
###xml 944 948 <span type="species:ncbi:10090">mice</span>
Autosomal recessive juvenile parkinsonism (AR-JP) is caused by mutations in the parkin gene which encodes an E3 ubiquitin-protein ligase. Parkin is thought to be critical for protecting dopaminergic neurons from toxic insults by targeting misfolded or oxidatively damaged proteins for proteasomal degradation. Surprisingly, mice with targeted deletions of parkin do not recapitulate robust behavioral or pathological signs of parkinsonism. Since Parkin is thought to protect against neurotoxic insults, we hypothesized that the reason Parkin-deficient mice do not develop parkinsonism is because they are not exposed to appropriate environmental triggers. To test this possibility, we challenged Parkin-deficient mice with neurotoxic regimens of either methamphetamine (METH) or 6-hydroxydopamine (6-OHDA). Because Parkin function has been linked to many of the pathways involved in METH and 6-OHDA toxicity, we predicted that Parkin-deficient mice would be more sensitive to the neurotoxic effects of these agents.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 154 158 <span type="species:ncbi:10090">mice</span>
###xml 265 269 <span type="species:ncbi:10090">mice</span>
We found no signs consistent with oxidative stress, ubiquitin dysfunction, or degeneration of striatal dopamine neuron terminals in aged Parkin-deficient mice. Moreover, results from behavioral, neurochemical, and immunoblot analyses indicate that Parkin-deficient mice are not more sensitive to dopaminergic neurotoxicity following treatment with METH or 6-OHDA.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 92 96 <span type="species:ncbi:10090">mice</span>
###xml 242 246 <span type="species:ncbi:10090">mice</span>
###xml 459 463 <span type="species:ncbi:10090">mice</span>
###xml 648 652 <span type="species:ncbi:10090">mice</span>
###xml 715 720 <span type="species:ncbi:9606">human</span>
###xml 725 730 <span type="species:ncbi:10090">mouse</span>
###xml 802 807 <span type="species:ncbi:10090">mouse</span>
###xml 829 835 <span type="species:ncbi:9606">humans</span>
###xml 916 920 <span type="species:ncbi:10090">mice</span>
Our results suggest that the absence of a robust parkinsonian phenotype in Parkin-deficient mice is not due to the lack of exposure to environmental triggers with mechanisms of action similar to METH or 6-OHDA. Nevertheless, Parkin-deficient mice could be more sensitive to other neurotoxins, such as rotenone or MPTP, which have different mechanisms of action; therefore, identifying conditions that precipitate parkinsonism specifically in Parkin-deficient mice would increase the utility of this model and could provide insight into the mechanism of AR-JP. Alternatively, it remains possible that the absence of parkinsonism in Parkin-deficient mice could reflect fundamental differences between the function of human and mouse Parkin, or the existence of a redundant E3 ubiquitin-protein ligase in mouse that is not found in humans. Therefore, additional studies are necessary to understand why Parkin-deficient mice do not display robust signs of parkinsonism.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
Parkinson's disease (PD) is a common neurological disorder that leads to severe motor disabilities due to degeneration of dopaminergic neurons in the substantia nigra pars compacta. Although it remains unclear how or why these specific neurons degenerate, the mechanisms likely depend on both environmental and genetic factors.
###end p 9
###begin p 10
###xml 206 207 206 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 208 209 208 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 407 408 407 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
Epidemiological studies suggest that exposure to certain environmental factors, such as pesticides, well water, heavy metals, solvents, or carbon monoxide, significantly increase the risk of developing PD [1-4]. These environmental factors are thought to inhibit mitochondrial function, increase oxidative stress, damage proteins, and inhibit ubiquitin-proteasome system (UPS) function in dopamine neurons [5].
###end p 10
###begin p 11
###xml 60 67 60 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 109 110 109 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 311 312 311 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 313 314 313 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 413 414 413 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 491 493 491 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 601 602 601 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 603 605 603 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 649 651 649 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 652 654 652 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 712 719 712 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 779 781 779 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 782 784 782 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 818 825 818 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 54 59 <span type="species:ncbi:9606">human</span>
Genetic studies have determined that mutations in the human parkin gene can cause AR-JP, a PD-like disorder [6]. The Parkin protein is a widely expressed, E3 ubiquitin-protein ligase that is thought to target proteins, possibly those oxidatively damaged from environmental insults, for proteasomal degradation [6-8]. In the absence of Parkin function, oxidatively damaged proteins may not be cleared by the cell [9], and these proteins could in turn propagate damage to additional proteins [10]. Parkin may also be involved in the unfolded protein response (UPR) to endoplasmic reticulum (ER) stress [8,11] or in maintaining mitochondrial function [12,13]. Dysfunction in either of these pathways as a result of parkin mutations could also cause oxidative stress and cell death [14,15]. Understanding how mutations in parkin lead to dopamine neuron cell death could provide insight into the mechanism and treatment of other PD-like disorders.
###end p 11
###begin p 12
###xml 32 39 32 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 123 130 123 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 136 141 136 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Park2</italic>
###xml 214 221 214 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 298 305 298 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 377 379 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 380 382 380 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 635 642 635 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 727 729 727 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 730 732 730 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 798 800 798 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 78 82 <span type="species:ncbi:10090">mice</span>
###xml 117 122 <span type="species:ncbi:10090">mouse</span>
###xml 236 242 <span type="species:ncbi:9606">humans</span>
###xml 266 270 <span type="species:ncbi:10090">mice</span>
###xml 495 499 <span type="species:ncbi:10090">mice</span>
###xml 613 621 <span type="species:ncbi:9606">patients</span>
###xml 852 856 <span type="species:ncbi:10090">mice</span>
To investigate how mutations in parkin lead to parkinsonism, several lines of mice with a targeted disruption of the mouse parkin gene, Park2, have been generated. Given the overwhelming evidence that mutations in parkin cause AR-JP in humans, it is surprising that mice with targeted deletions of parkin do not develop robust behavioral or pathological signs of parkinsonism [16-19]. These findings suggest that loss of Parkin function may not be sufficient for dopamine neuron degeneration in mice. Consistent with this idea, the age of onset, disease progression, and symptom severity can differ between AR-JP patients with similar parkin mutations, suggesting that environmental factors may contribute to the pathogenesis [20-22]. Since Parkin is thought to protect against neurotoxic insults [23], we hypothesized that the reason Parkin-deficient mice do not develop parkinsonism is because they are not exposed to appropriate environmental stress.
###end p 12
###begin p 13
###xml 63 65 63 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 127 131 <span type="species:ncbi:10090">mice</span>
###xml 294 300 <span type="species:ncbi:9606">humans</span>
###xml 345 349 <span type="species:ncbi:10090">mice</span>
In this study, we extended our initial characterization study [16] by specifically investigating whether aged Parkin-deficient mice exhibit signs of ubiquitin dysregulation, increased oxidative damage to proteins, or dopamine terminal degeneration consistent with Parkin's proposed function in humans. We also evaluated whether Parkin-deficient mice are more sensitive to nigrostriatal injury following treatment with the neurotoxins 6-OHDA or METH.
###end p 13
###begin p 14
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 235 237 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 405 407 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 489 491 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
6-OHDA is a hydroxylated dopamine analogue that is readily oxidized causing ROS-mediated damage [24], mitochondrial dysfunction [25], ER stress, activation of the UPR [26,27], and an increase in ubiquitin-mediated protein degradation [28]. Some of these effects are likely mediated by iron-dependent mechanisms [29,30]. Moreover, 6-OHDA toxicity is exacerbated by ubiquitin-proteasome system dysfunction [28], and Parkin-overexpression in cell culture can protect against 6-OHDA toxicity [31].
###end p 14
###begin p 15
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 226 228 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 302 304 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 387 389 387 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 456 458 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 459 461 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 508 510 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 564 566 564 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 635 637 635 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 718 720 718 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 721 723 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
METH is a drug of abuse that releases vesicular dopamine into the cytoplasm and extracellular space [32]. The displaced dopamine can be readily oxidized [33] and may underlie the observed increases in hydroxyl radical levels [34], oxidatively damaged proteins [35], and endogenous formation of 6-OHDA [36] following METH treatment. METH neurotoxicity can inhibit mitochondrial function [37,38] and can be modified by alterations in mitochondrial function [39,40]. Moreover, METH toxicity involves autophagy [41], resembles ubiquitin-proteasome system dysfunction [42], and can activate ER stress and mitochondrial cell-death pathways [43]. There is also evidence that METH toxicity is partially mediated by glutamate [44,45].
###end p 15
###begin p 16
###xml 137 141 <span type="species:ncbi:10090">mice</span>
Because Parkin function has been linked to many of the pathways involved in METH and 6-OHDA toxicity, we predicted that Parkin-deficient mice would be more sensitive to the neurotoxic effects of these agents.
###end p 16
###begin title 17
Results
###end title 17
###begin title 18
###xml 22 26 <span type="species:ncbi:10090">mice</span>
Aged Parkin-deficient mice do not exhibit signs consistent with ubiquitin dysfunction, oxidative stress, or dopamine neuron terminal degeneration
###end title 18
###begin p 19
###xml 286 287 286 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 557 559 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 682 684 682 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 757 759 757 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 907 908 907 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1121 1122 1121 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 43 47 <span type="species:ncbi:10090">mice</span>
###xml 181 185 <span type="species:ncbi:10090">mice</span>
###xml 187 189 <span type="species:ncbi:10090">WT</span>
###xml 212 216 <span type="species:ncbi:10090">mice</span>
###xml 218 220 <span type="species:ncbi:10090">KO</span>
###xml 333 337 <span type="species:ncbi:10090">mice</span>
###xml 691 699 <span type="species:ncbi:9606">patients</span>
###xml 885 887 <span type="species:ncbi:10090">WT</span>
###xml 892 894 <span type="species:ncbi:10090">KO</span>
###xml 895 899 <span type="species:ncbi:10090">mice</span>
###xml 978 982 <span type="species:ncbi:10090">mice</span>
###xml 1086 1088 <span type="species:ncbi:10090">WT</span>
###xml 1093 1095 <span type="species:ncbi:10090">KO</span>
###xml 1096 1100 <span type="species:ncbi:10090">mice</span>
We predicted that the absence of Parkin in mice would lead to dysregulation of total ubiquitin levels; however, there was no difference between aged, 22-month-old wild-type control mice (WT) and Parkin-deficient mice (KO) using immunoblot analysis of striatal or cortical tissue (Table 1). We also hypothesized that Parkin-deficient mice would exhibit an accumulation of oxidized proteins. Oxidation of proteins by reactive oxygen species and other reactive species, such as 4-hydroxy-2-nonenal from lipid peroxidation, produces protein carbonyl derivates [46]. Protein carbonyl levels have been extensively used as a sensitive marker for oxidative stress in various model systems [46], and patients with PD exhibit a general increase in protein carbonyls [47]. Using immunoblot analysis, we detected no differences in the levels of striatal or cortical protein carbonyls between aged WT and KO mice (Table 1). To evaluate dopamine neuron terminal integrity in Parkin-deficient mice, we performed immunoblot analysis of striatal dopamine transporter (DAT) levels. No difference between WT and KO mice was detected (Table 1).
###end p 19
###begin title 20
###xml 17 21 <span type="species:ncbi:10090">mice</span>
Parkin-deficient mice are not more sensitive to 6-OHDA toxicity
###end title 20
###begin p 21
###xml 38 42 <span type="species:ncbi:10090">mice</span>
###xml 111 113 <span type="species:ncbi:10090">WT</span>
###xml 118 120 <span type="species:ncbi:10090">KO</span>
###xml 121 125 <span type="species:ncbi:10090">mice</span>
###xml 196 200 <span type="species:ncbi:10090">Mice</span>
###xml 338 340 <span type="species:ncbi:10090">WT</span>
###xml 341 345 <span type="species:ncbi:10090">mice</span>
###xml 374 376 <span type="species:ncbi:10090">KO</span>
###xml 377 381 <span type="species:ncbi:10090">mice</span>
To determine whether Parkin-deficient mice are more sensitive to the neurotoxin 6-OHDA, we treated 3-month-old WT and KO mice with a unilateral, intrastriatal injection of saline (SAL) or 6-OHDA. Mice were treated with either a 4 mug or 8 mug dose of 6-OHDA because our objective was to find a dose that would cause mild neurotoxicity in WT mice but severe neurotoxicity in KO mice.
###end p 21
###begin p 22
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 423 425 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 784 785 782 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 785 790 783 788 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1,22 </sub>
###xml 797 799 795 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 821 822 818 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 822 827 819 824 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1,14 </sub>
###xml 835 837 832 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1102 1103 1097 1098 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1103 1108 1098 1103 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1,36 </sub>
###xml 1115 1117 1110 1112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1266 1268 1261 1263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 1322 1323 1316 1317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1323 1328 1317 1322 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1,22 </sub>
###xml 1335 1337 1329 1331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1359 1360 1352 1353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1360 1365 1353 1358 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1,14 </sub>
###xml 1372 1374 1365 1367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 191 195 <span type="species:ncbi:10090">Mice</span>
###xml 621 625 <span type="species:ncbi:10090">mice</span>
###xml 684 688 <span type="species:ncbi:10090">mice</span>
###xml 925 929 <span type="species:ncbi:10090">mice</span>
###xml 1024 1028 <span type="species:ncbi:10090">mice</span>
###xml 1203 1205 <span type="species:ncbi:10090">WT</span>
###xml 1210 1212 <span type="species:ncbi:10090">KO</span>
###xml 1213 1217 <span type="species:ncbi:10090">mice</span>
Beginning 14 days after surgery, analyses of apomorphine (APO)- and amphetamine (AMPH)- induced rotational behaviors were conducted to evaluate the consequences of 6-OHDA neurotoxicity [48]. Mice were first challenged with the postsynaptic dopamine receptor agonist APO. Rotations away from the lesioned side (contralateral) reflect postsynaptic dopamine receptor supersensitivity following striatal dopamine depletion [49,50]. Repeated measures ANOVAs were used to compare the number of net rotations following a subcutaneous injection of SAL versus APO. There was no significant effect of APO on rotational behavior in mice that received an intrastriatal injection of SAL; however, mice treated with 4 or 8 mug 6-OHDA demonstrated significant contralateral rotations (4 mug 6-OHDA, F1,22 = 4.6, p = 0.04; 8 mug 6-OHDA, F1,14 = 12.7, p = 0.003). Moreover, there was a dose-dependent effect of 6-OHDA on rotational behavior; mice treated with 8 mug 6-OHDA exhibited significantly greater contralateral rotations compared to mice treated with 4 mug 6-OHDA (APO Treatment x 6-OHDA Treatment interaction, F1,36 = 8.7, p = 0.006). However, there was no difference in APO-induced rotational behavior between WT and KO mice treated with SAL or either dose of 6-OHDA (Fig. 1A; Genotype x APO Treatment interaction: 4 mug 6-OHDA, F1,22 = 1.5, p = 0.24; 8 mug 6-OHDA, F1,14 = 0.2, p = 0.65).
###end p 22
###begin p 23
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 344 345 344 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 345 350 345 350 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1,10 </sub>
###xml 357 359 357 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 492 493 490 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 493 498 491 496 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1,22 </sub>
###xml 505 507 503 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 529 530 526 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 530 535 527 532 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1,14 </sub>
###xml 543 545 540 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 746 748 743 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 803 804 799 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 804 809 800 805 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1,22 </sub>
###xml 816 818 812 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 840 841 835 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 841 846 836 841 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1,14 </sub>
###xml 853 855 848 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 28 32 <span type="species:ncbi:10090">mice</span>
###xml 290 294 <span type="species:ncbi:10090">mice</span>
###xml 368 372 <span type="species:ncbi:10090">Mice</span>
###xml 674 676 <span type="species:ncbi:10090">WT</span>
###xml 681 683 <span type="species:ncbi:10090">KO</span>
###xml 684 688 <span type="species:ncbi:10090">mice</span>
Fifteen days after surgery, mice were challenged with AMPH to evaluate rotational behavior. Because AMPH causes presynaptic dopamine release, rotations towards the lesioned side (ipsilateral) reflect loss of striatal dopamine terminals [49,50]. AMPH had no effect on rotational behavior in mice that received an intrastriatal injection of SAL (F1,10 = 2.9, p = 0.12). Mice that received 4 or 8 mug 6-OHDA demonstrated significant ipsilateral rotations following AMPH treatment (4 mug 6-OHDA, F1,22 = 5.8, p = 0.02; 8 mug 6-OHDA, F1,14 = 16.9, p = 0.001); however, a dose-dependent effect of 6-OHDA on AMPH-induced rotations was not observed. There was no difference between WT and KO mice in AMPH-induced rotational behavior at either dose (Fig. 1B; Genotype x AMPH Treatment interaction: 4 mug 6-OHDA, F1,22 = 0.5, p = 0.49; 8 mug 6-OHDA, F1,14 = 0.0, p = 0.93).
###end p 23
###begin p 24
###xml 639 640 639 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 640 645 640 645 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1,10 </sub>
###xml 652 654 652 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 832 833 829 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 833 838 830 835 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1,22 </sub>
###xml 846 848 843 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 872 873 868 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 873 878 869 874 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1,14 </sub>
###xml 886 888 882 884 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 975 977 971 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 1034 1035 1029 1030 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1035 1040 1030 1035 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1,22 </sub>
###xml 1047 1049 1042 1044 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1071 1072 1065 1066 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1072 1077 1066 1071 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1,14 </sub>
###xml 1084 1086 1078 1080 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1265 1266 1257 1258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1266 1271 1258 1263 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1,36 </sub>
###xml 1278 1280 1270 1272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 939 941 <span type="species:ncbi:10090">WT</span>
###xml 946 948 <span type="species:ncbi:10090">KO</span>
###xml 949 953 <span type="species:ncbi:10090">mice</span>
Eighteen days after surgery, striatal samples from the injected and uninjected sides were collected for neurochemical analyses to determine the concentrations of the neurotransmitters norepinephrine (NE), dopamine, and serotonin (5-HT); the dopamine-related metabolites 3-methoxytyramine (3-MT), 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA); and the 5-HT-related metabolite 5-hydroxyindoleacetic acid (5-HIAA). For each animal, data from the treated (injected) striatum was compared to data from the untreated striatum using repeated measures ANOVAs. Intrastriatal injection of SAL had no effect on dopamine levels (F1,10 = 0.0, p = 0.95) or any other neurochemicals measured (3-MT, DOPAC, HVA, NE, 5-HT, 5-HIAA). Treatment with 4 mug or 8 mug 6-OHDA led to a ~40% reduction in dopamine levels (4 mug 6-OHDA, F1,22 = 24.0, p < 0.0001; 8 mug 6-OHDA, F1,14 = 14.8, p = 0.002); however, there was no difference between WT and KO mice at either dose (Fig. 1C; Genotype x 6-OHDA Treatment interaction: 4 mug 6-OHDA, F1,22 = 0.1, p = 0.78; 8 mug 6-OHDA, F1,14 = 0.7, p = 0.41). Although treatment with 8 mug 6-OHDA led to more APO-induced rotational behavior compared to 4 mug 6-OHDA, it did not produce a significantly greater dopamine depletion (F1,36 = 0.4, p = 0.54). Significant reductions in DOPAC, HVA, 3-MT, and dopamine/DOPAC were observed in striata treated with 6-OHDA; Genotype had no effect on these decreases (data not shown). 5-HT or 5-HIAA levels were not reduced on the 6-OHDA-lesioned side, but there was a trend towards decreased NE on the lesioned side with no effect of Genotype (data not shown).
###end p 24
###begin title 25
###xml 17 21 <span type="species:ncbi:10090">mice</span>
Parkin-deficient mice are not more sensitive to METH toxicity
###end title 25
###begin p 26
###xml 38 42 <span type="species:ncbi:10090">mice</span>
###xml 98 100 <span type="species:ncbi:10090">WT</span>
###xml 105 107 <span type="species:ncbi:10090">KO</span>
###xml 108 112 <span type="species:ncbi:10090">mice</span>
###xml 178 182 <span type="species:ncbi:10090">Mice</span>
###xml 358 360 <span type="species:ncbi:10090">WT</span>
###xml 361 365 <span type="species:ncbi:10090">mice</span>
###xml 394 396 <span type="species:ncbi:10090">KO</span>
###xml 397 401 <span type="species:ncbi:10090">mice</span>
To determine whether Parkin-deficient mice are more sensitive to the neurotoxin METH, 3-month-old WT and KO mice were treated with repeated, acute administration of SAL or METH. Mice received either a low (2.5 mg/kg body weight) or moderate dose (5.0 mg/kg body weight) of METH because our objective was to find a dose that would cause mild neurotoxicity in WT mice but severe neurotoxicity in KO mice.
###end p 26
###begin p 27
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 596 598 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 846 847 846 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 847 852 847 852 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1,29 </sub>
###xml 859 861 859 861 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 988 990 988 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 992 994 992 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 1013 1014 1013 1014 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1014 1019 1014 1019 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1,29 </sub>
###xml 1026 1028 1026 1028 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1065 1066 1065 1066 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1066 1071 1066 1071 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1,29 </sub>
###xml 1078 1080 1078 1080 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1260 1262 1256 1258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 37 39 <span type="species:ncbi:10090">KO</span>
###xml 40 44 <span type="species:ncbi:10090">mice</span>
###xml 292 294 <span type="species:ncbi:10090">WT</span>
###xml 299 301 <span type="species:ncbi:10090">KO</span>
###xml 302 306 <span type="species:ncbi:10090">mice</span>
###xml 489 491 <span type="species:ncbi:10090">WT</span>
###xml 496 498 <span type="species:ncbi:10090">KO</span>
###xml 499 503 <span type="species:ncbi:10090">mice</span>
###xml 580 582 <span type="species:ncbi:10090">WT</span>
###xml 587 589 <span type="species:ncbi:10090">KO</span>
###xml 590 594 <span type="species:ncbi:10090">mice</span>
###xml 689 691 <span type="species:ncbi:10090">WT</span>
###xml 696 698 <span type="species:ncbi:10090">KO</span>
###xml 699 703 <span type="species:ncbi:10090">mice</span>
###xml 942 944 <span type="species:ncbi:10090">WT</span>
###xml 949 951 <span type="species:ncbi:10090">KO</span>
###xml 952 956 <span type="species:ncbi:10090">mice</span>
###xml 1132 1134 <span type="species:ncbi:10090">WT</span>
###xml 1139 1141 <span type="species:ncbi:10090">KO</span>
###xml 1142 1146 <span type="species:ncbi:10090">mice</span>
###xml 1186 1188 <span type="species:ncbi:10090">WT</span>
###xml 1215 1217 <span type="species:ncbi:10090">KO</span>
We have previously demonstrated that KO mice have a normal hyperlocomotor response to repeated administration of AMPH (4.0 mg/kg body weight), a psychostimulant similar to METH [16]. Because METH neurotoxicity can be modified by decreasing METH-induced hyperthermia [51], differences between WT and KO mice in body temperature regulation would confound interpretation of results. Body temperature regulation over 24 hr and in response to a cold challenge is indistinguishable between aged WT and KO mice; moreover, there are no differences in body temperature between 3-month-old WT and KO mice [16]. In the present study, we monitored body temperature before and during METH treatment in WT and KO mice. Treatment with METH at 5.0 mg/kg led to a significantly greater METH-induced hyperthermia compared to treatment with 2.5 mg/kg (Dose effect, F1,29 = 7.1, p = 0.01); however, there were no significant body temperature differences between WT and KO mice following METH treatment (Fig. 2A, 2B; Genotype effect, F1,29 = 0.3, p = 0.56; Genotype x Dose interaction, F1,29 = 2.4, p = 0.13). The mean body weight among all 3-month-old WT and KO mice used for this study was not different (WT = 32.0 +/- 0.4 g, N = 47; KO = 31.7 +/- 0.5 g, N = 57; Student t-test, p = 0.69).
###end p 27
###begin p 28
###xml 213 214 213 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 214 219 214 219 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2,46 </sub>
###xml 227 229 227 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 383 384 383 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 384 389 384 389 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1,32 </sub>
###xml 397 399 397 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 533 535 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 554 555 554 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 555 560 555 560 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1,46 </sub>
###xml 567 569 567 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 611 612 611 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 612 617 612 617 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2,46 </sub>
###xml 624 626 624 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1097 1098 1097 1098 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1098 1103 1098 1103 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1,20 </sub>
###xml 1111 1113 1111 1113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1185 1187 1185 1187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2D</xref>
###xml 1223 1224 1223 1224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1224 1229 1224 1229 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1,20 </sub>
###xml 1236 1238 1236 1238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1164 1166 <span type="species:ncbi:10090">WT</span>
###xml 1171 1173 <span type="species:ncbi:10090">KO</span>
###xml 1174 1178 <span type="species:ncbi:10090">mice</span>
Seven days following treatment, METH neurotoxicity was evaluated by neurochemical and immunoblot analyses. There was a significant reduction in striatal dopamine levels following METH treatment (Treatment effect, F2,46 = 45.4, p < 0.0001). Treatment with METH at 5.0 mg/kg produced a significantly greater dopamine depletion compared to 2.5 mg/kg (80% versus 50% dopamine reduction; F1,32 = 30.0, p < 0.0001). However, we detected no difference between genotypes in the magnitude of dopamine depletion following METH treatment (Fig. 2C; Genotype effect, F1,46 = 0.9, p = 0.34; Genotype x Treatment interaction, F2,46 = 0.2, p = 0.86). We also observed significant reductions in the dopamine metabolites DOPAC, HVA, and 3-MT following METH treatment, but there were no differences between genotypes in these reductions (data not shown). Reductions in striatal NE, 5-HT, or 5-HIAA were not detected (data not shown). Immunoblot analysis of striatal DAT levels, a marker for dopamine neuron terminal integrity, demonstrated a 30% reduction following treatment with METH (2.5 mg/kg; Treatment effect, F1,20 = 10.3, p = 0.004); however, there was no difference between WT and KO mice (Fig. 2D; Genotype x Treatment interaction, F1,20 = 1.6, p = 0.22).
###end p 28
###begin title 29
Discussion
###end title 29
###begin p 30
###xml 454 456 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 618 619 618 619 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 620 621 620 621 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 659 661 659 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 799 801 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 953 955 953 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1466 1468 1466 1468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 29 33 <span type="species:ncbi:10090">mice</span>
###xml 448 452 <span type="species:ncbi:10090">mice</span>
###xml 836 840 <span type="species:ncbi:10090">mice</span>
###xml 947 951 <span type="species:ncbi:10090">mice</span>
###xml 1016 1018 <span type="species:ncbi:10090">WT</span>
###xml 1023 1025 <span type="species:ncbi:10090">KO</span>
###xml 1026 1030 <span type="species:ncbi:10090">mice</span>
###xml 1127 1131 <span type="species:ncbi:10090">mice</span>
###xml 1160 1162 <span type="species:ncbi:10090">WT</span>
###xml 1163 1167 <span type="species:ncbi:10090">mice</span>
###xml 1212 1216 <span type="species:ncbi:10090">mice</span>
###xml 1411 1413 <span type="species:ncbi:10090">WT</span>
###xml 1418 1420 <span type="species:ncbi:10090">KO</span>
###xml 1421 1425 <span type="species:ncbi:10090">mice</span>
We expected Parkin-deficient mice to demonstrate increased signs of oxidized proteins as a result of increased pro-oxidant activity, for example due to mitochondrial dysfunction; decreased antioxidant activity, for example due to dysregulation of glutathione levels; or decreased protein clearance due to dysfunction of the ubiquitin proteasome system. Previous studies have identified increased protein carbonyls in the brains of Parkin-deficient mice [13], a slight increase in GSH levels specifically in the striatum, and an increase in DOPAC/3-MT levels consistent with a shift towards dopamine metabolism by the H2O2-producing monoamine oxidase pathway [18]. A slight reduction in striatal DAT levels was also previously observed, which may reflect initial damage to dopamine neuron terminals [18]. In this study, Parkin-deficient mice did not exhibit increased levels of protein carbonyls, and consistent with our previous report using aged mice [16], we found no difference in DOPAC/3-MT levels between young WT and KO mice (data not shown). Moreover, levels of total ubiquitin and striatal DAT in aged Parkin-deficient mice were indistinguishable from WT mice. Our results suggest that loss of Parkin in mice does not lead to robust oxidative stress, ubiquitin dysfunction, or dopamine neuron terminal degeneration. Nevertheless, we cannot rule out the possibility that differences in oxidation between WT and KO mice are limited to a few specific proteins [52].
###end p 30
###begin p 31
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 385 387 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 561 563 561 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 564 566 564 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 732 734 732 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 766 768 766 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 99 104 <span type="species:ncbi:10090">mouse</span>
###xml 179 184 <span type="species:ncbi:10090">mouse</span>
###xml 457 462 <span type="species:ncbi:10090">mouse</span>
###xml 586 590 <span type="species:ncbi:10090">mice</span>
The current study extends the number of inconsistent findings reported in several Parkin-deficient mouse models [13,16-19]. Reasons for discrepancies among these Parkin-deficient mouse models have been previously discussed and include differences in experimental technique, differences in genetic background, differences in the gene targeting strategy, or confounds of gene targeting [16]. Of biological significance, the type of targeted mutation in these mouse models could differentially affect expression of potential Parkin isoforms with unique functions [53-55]. Parkin-deficient mice used in this study lack exon 2, which encodes most of the ubiquitin-like domain believed to be required for interacting with the proteasome [56] and ubiquitinated substrates [57].
###end p 31
###begin p 32
###xml 197 204 197 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 262 264 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 353 360 353 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 474 476 474 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 477 479 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 619 626 619 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 733 770 733 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mitochondrial superoxide dismutase 2 </italic>
###xml 771 775 771 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sod2</italic>
###xml 805 812 805 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 820 822 820 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 903 908 903 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sod2 </italic>
###xml 1073 1075 1073 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 1076 1078 1076 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 1108 1113 1108 1113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sod2 </italic>
###xml 49 53 <span type="species:ncbi:10090">mice</span>
###xml 227 229 <span type="species:ncbi:10090">KO</span>
###xml 230 234 <span type="species:ncbi:10090">mice</span>
###xml 253 255 <span type="species:ncbi:10090">WT</span>
###xml 256 260 <span type="species:ncbi:10090">mice</span>
###xml 413 417 <span type="species:ncbi:10090">mice</span>
###xml 595 599 <span type="species:ncbi:10090">mice</span>
###xml 674 676 <span type="species:ncbi:10090">WT</span>
###xml 681 683 <span type="species:ncbi:10090">KO</span>
###xml 684 688 <span type="species:ncbi:10090">mice</span>
###xml 937 942 <span type="species:ncbi:10090">mouse</span>
###xml 1167 1171 <span type="species:ncbi:10090">mice</span>
Interpretation of studies using Parkin-deficient mice can be complicated because a mixed B6;129 genetic background was used in this study and most previous studies; therefore, many genes linked to parkin will be 129 derived in KO mice and B6 derived in WT mice [16]. Even after 12 backcrosses to the B6 genetic background, ~16 cM surrounding the mutant parkin allele could remain 129 derived; however, in control mice the corresponding region will likely remain B6 derived [58,59]. It is possible that the increased oxidative stress and protein carbonyls previously reported in Parkin-deficient mice are not due to the parkin mutation but reflect strain differences between WT and KO mice in these closely linked genes. For example, mitochondrial superoxide dismutase 2 (Sod2), which is tightly linked to parkin (~2 cM [60]), is involved in mitochondrial function and protects against oxidative stress. Sod2 polymorphisms between inbred mouse strains have been described and can lead to a reduction in specific activity of the protein and an increase in protein carbonyls [61,62]. It is very likely that the Sod2 gene will differ between Parkin-deficient and control mice unless appropriate breeding strategies are employed.
###end p 32
###begin p 33
###xml 504 506 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 892 894 892 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 895 897 895 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 1067 1069 1067 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1090 1092 1090 1092 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 69 73 <span type="species:ncbi:10090">mice</span>
###xml 235 239 <span type="species:ncbi:10090">mice</span>
###xml 393 395 <span type="species:ncbi:10090">WT</span>
###xml 400 402 <span type="species:ncbi:10090">KO</span>
###xml 403 407 <span type="species:ncbi:10090">mice</span>
###xml 623 627 <span type="species:ncbi:10090">mice</span>
###xml 1141 1145 <span type="species:ncbi:10090">mice</span>
Despite the inconsistencies among studies involving Parkin-deficient mice, we sought to determine whether there were any functional consequences of Parkin-deficiency following neurotoxic treatment with 6-OHDA or METH. Parkin-deficient mice were not more sensitive to 6-OHDA neurotoxicity. Specifically, the dose-dependent, behavioral response to 6-OHDA treatment was indistinguishable between WT and KO mice. Moreover, because APO-induced rotational behavior reflects dopamine-receptor supersensitivity [49,50], our results suggest that the compensatory mechanisms underlying this phenomenon are intact in Parkin-deficient mice. Despite the dose-dependent increase in APO-induced rotational behavior, we were unable to detect a dose-dependent effect of 6-OHDA on dopamine depletion, thereby supporting a role for variables other than the extent of dopamine depletion on APO-induced rotation [49,50]. With regard to the role of Parkin in 6-OHDA toxicity, it has been observed that overexpression of Parkin protects against 6-OHDA toxicity in some cell culture models [31] but not in others [63]. Our results suggest that Parkin-deficiency in mice does not dramatically affect the pathways involved in 6-OHDA neurotoxicity.
###end p 33
###begin p 34
###xml 152 154 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 370 372 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 484 486 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 601 603 601 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 758 760 758 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 761 763 761 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 894 896 894 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1025 1027 1025 1027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 136 138 <span type="species:ncbi:10090">WT</span>
###xml 143 145 <span type="species:ncbi:10090">KO</span>
###xml 146 150 <span type="species:ncbi:10090">mice</span>
###xml 281 286 <span type="species:ncbi:10090">mouse</span>
###xml 745 750 <span type="species:ncbi:10090">mouse</span>
We previously reported that locomotion following treatment with AMPH, which is chemically related to METH, is indistinguishable between WT and KO mice [16]; in this study we demonstrate that there is no difference in METH-induced hyperthermia. Previous studies have suggested that mouse Parkin is involved in regulating dopaminergic and glutamatergic neurotransmission [18]. Our pharmacological, behavioral, neurochemical, and toxicity studies are not consistent with these findings [16]. It was also shown that Parkin can protect dopamine neurons in a cell-culture model of glutamate excitotoxicity [64]. Our results indicate that this finding cannot be extended to METH-related glutamate toxicity of dopaminergic neurons in a Parkin-deficient mouse model [44,45]. It has also been proposed that Parkin is involved in METH toxicity because Parkin-immunoreactive aggregates have been observed [42] and levels of Parkin and Pael-R, a putative target for Parkin-mediated ubiquitination, are decreased following METH treatment [65]. We found that Parkin was not essential for METH or 6-OHDA neurotoxicity.
###end p 34
###begin p 35
###xml 331 338 331 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 489 495 489 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin</italic>
###xml 505 527 505 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tumor necrosis factor </italic>
###xml 572 574 572 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 61 65 <span type="species:ncbi:10090">mice</span>
###xml 400 402 <span type="species:ncbi:10090">KO</span>
###xml 403 407 <span type="species:ncbi:10090">mice</span>
###xml 643 647 <span type="species:ncbi:10090">mice</span>
###xml 861 865 <span type="species:ncbi:10090">mice</span>
Although our results suggest that Parkin-deficiency in young mice does not greatly modify susceptibility of dopaminergic neurons to acute METH or 6-OHDA neurotoxicity, interpretation is complicated by our use of a mixed genetic background. We cannot rule out the possibility that strain differences in genes linked to the targeted parkin allele may confer protection against toxicity specifically in KO mice thereby masking an effect due to Parkin-deficiency. For example, genes linked to parkin, such as tumor necrosis factor (~13 cM), are known to modify METH toxicity [66]. To avoid this complication, future work should utilize coisogenic mice as controls, especially when small differences between genotypes are detected. Despite this potential confound, Parkin does not appear to play a critical role in protection against METH or 6-OHDA neurotoxicity in mice.
###end p 35
###begin p 36
###xml 405 407 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 66 70 <span type="species:ncbi:10090">mice</span>
###xml 209 213 <span type="species:ncbi:10090">mice</span>
###xml 701 705 <span type="species:ncbi:10090">mice</span>
###xml 791 795 <span type="species:ncbi:10090">mice</span>
###xml 890 894 <span type="species:ncbi:10090">mice</span>
###xml 982 986 <span type="species:ncbi:10090">mice</span>
Our results do not rule out the possibility that Parkin-deficient mice could be more sensitive to other neurotoxins which have different mechanisms of action than METH or 6-OHDA. For example, Parkin-deficient mice could be more sensitive to the neurotoxic effects of rotenone, maneb, paraquat, MPTP, or genetic overexpression of putative Parkin substrates, such as aminoacyl-tRNA synthetase cofactor p38 [67]. Moreover, interpretation of our results is limited by the specific neurotoxic regimens used in our experiments and the nature of negative findings; we cannot exclude the possibility that alternative METH or 6-OHDA neurotoxic regimens could reveal a latent susceptibility of Parkin-deficient mice to these agents. For example, our study utilized an acute model of toxicity in young mice; Parkin may protect dopaminergic neurons from specific, chronic insults, particularly in aged mice. Identifying conditions that precipitate parkinsonism specifically in Parkin-deficient mice would increase the utility of this model and could provide insight into the mechanism of AR-JP.
###end p 36
###begin p 37
###xml 88 92 <span type="species:ncbi:10090">mice</span>
###xml 220 224 <span type="species:ncbi:10090">mice</span>
###xml 318 322 <span type="species:ncbi:10090">mice</span>
###xml 364 370 <span type="species:ncbi:9606">humans</span>
###xml 429 435 <span type="species:ncbi:9606">humans</span>
###xml 452 456 <span type="species:ncbi:10090">mice</span>
###xml 537 541 <span type="species:ncbi:10090">mice</span>
Alternatively, despite the limitations of our study, the findings that Parkin-deficient mice are not more sensitive to METH or 6-OHDA could suggest that the absence of a robust parkinsonian phenotype in Parkin-deficient mice is not due to the lack of exposure to appropriate environmental triggers. Parkin function in mice could be fundamentally different than in humans, or a redundant E3 ubiquitin-protein ligase, not found in humans, could exist in mice. Therefore, additional studies are necessary to understand why Parkin-deficient mice do not display robust signs of parkinsonism.
###end p 37
###begin title 38
Conclusion
###end title 38
###begin p 39
###xml 22 26 <span type="species:ncbi:10090">mice</span>
###xml 186 190 <span type="species:ncbi:10090">mice</span>
Aged Parkin-deficient mice do not display signs consistent with oxidative stress, ubiquitin dysfunction, or dopamine neuron terminal degeneration. Moreover, 3-month-old Parkin-deficient mice on a mixed B6;129 genetic background are not more sensitive to the acute neurotoxic effects of METH or 6-OHDA.
###end p 39
###begin title 40
Methods
###end title 40
###begin title 41
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 41
###begin p 42
###xml 51 58 51 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">parkin </italic>
###xml 66 71 66 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Park2</italic>
###xml 71 77 71 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tm1Rpa</italic>
###xml 71 77 71 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>tm1Rpa</italic></sup>
###xml 77 83 77 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Park2</italic>
###xml 83 89 83 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tm1Rpa</italic>
###xml 83 89 83 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>tm1Rpa</italic></sup>
###xml 124 129 124 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Park2</italic>
###xml 129 130 129 130 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 130 136 130 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Park2</italic>
###xml 136 137 136 137 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 169 174 169 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Park2</italic>
###xml 174 180 174 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tm1Rpa</italic>
###xml 174 180 174 180 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>tm1Rpa</italic></sup>
###xml 180 186 180 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Park2</italic>
###xml 186 188 186 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 601 650 601 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Guide for the Care and Use of Laboratory Animals </italic>
###xml 651 653 651 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 17 21 <span type="species:ncbi:10090">mice</span>
###xml 91 93 <span type="species:ncbi:10090">KO</span>
###xml 118 122 <span type="species:ncbi:10090">mice</span>
###xml 139 141 <span type="species:ncbi:10090">WT</span>
###xml 188 192 <span type="species:ncbi:10090">mice</span>
###xml 265 269 <span type="species:ncbi:10090">mice</span>
###xml 327 331 <span type="species:ncbi:10090">mice</span>
###xml 384 388 <span type="species:ncbi:10090">Mice</span>
Parkin-deficient mice, with a targeted deletion of parkin exon 2 (Park2tm1Rpa/Park2tm1Rpa; KO), and wild-type control mice (Park2+/Park2+; WT) were obtained by crossing Park2tm1Rpa/Park2+ mice on a mixed B6;129S4 genetic background [16]. Twenty-two-month old, male mice were used for analysis of aged tissue; 3-month old, male mice were used for METH and 6-OHDA toxicity experiments. Mice were housed in a specific-pathogen-free facility, maintained on a 12-hr light cycle, housed in groups, and provided with free access to water and food (5053, LabDiet; Richmond, IN). All procedures adhered to the Guide for the Care and Use of Laboratory Animals [68] and were approved by the University of Washington Institutional Animal Care and Use Committee.
###end p 42
###begin title 43
6-OHDA treatment
###end title 43
###begin p 44
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 1554 1556 1552 1554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 223 227 <span type="species:ncbi:10090">mice</span>
###xml 1015 1019 <span type="species:ncbi:10090">mice</span>
###xml 1077 1081 <span type="species:ncbi:10090">Mice</span>
###xml 1294 1298 <span type="species:ncbi:10090">Mice</span>
Mice received a unilateral, intrastriatal injection of SAL or a freshly prepared 6-OHDA solution (6-hydroxydopamine hydrobromide; Sigma-Aldrich; St. Louis, MO) using a stereotaxic surgical procedure [69,70]. 6-OHDA-treated mice received either a 4 mug or 8 mug dose, and all treatment preparations contained 0.02% ascorbic acid. Injections were targeted to the central caudate putamen using the following coordinates: 0.8 mm anterior to bregma, 2.0 mm lateral to bregma, and 3.6 mm ventral to the skull surface. Treatments were administered in a volume of 2.0 uL at a rate of 0.5 uL/min; after the injection, the needle was left in place for 5 min. Surgical treatments were performed without knowledge of genotypes. Fourteen and 15 days after surgery, rotational-behavior was evaluated in response to APO (apomorphine hydrochloride hemihydrate; 0.5 mg/kg body weight subcutaneously; Sigma-Aldrich) or AMPH (D-amphetamine sulfate salt; 2 mg/kg body weight intraperitoneally; Sigma-Aldrich), respectively. Individual mice were acclimated in a 16-cm diameter cylinder for 10 min. Mice were then administered SAL (either subcutaneously or intraperitoneally prior to APO or AMPH treatment, respectively), and the number of complete clockwise or counter-clockwise rotations were observed for 30 min. Mice were then administered either APO or AMPH and rotational behavior was scored for an additional 30 min. Rotational behavior was evaluated without knowledge of treatment or genotype. Eighteen days after surgery, striatal tissue was collected, as described [16], from both the injected and intact sides to evaluate integrity of dopamine-neuron terminals using neurochemical analyses.
###end p 44
###begin title 45
METH treatment
###end title 45
###begin p 46
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 179 183 <span type="species:ncbi:10090">mice</span>
Mice were administered repeated, intraperitoneal injections of SAL or METH ((+)-methamphetamine hydrochloride; Sigma-Aldrich) every 2 hr for a total of 4 injections. METH-treated mice received either a low (2.5 mg/kg body weight for each injection) or moderate (5.0 mg/kg) neurotoxic regimen. Body temperature was monitored every hour during METH treatment using a subcutaneously implanted, programmable, temperature transponder (Bio Medic Data Systems; Seaford, DE). Seven days after treatment, striatal tissue was harvested to assess integrity of dopamine-neuron terminals using neurochemical and immunoblot analyses. Treatments were administered and tissue was collected without knowledge of genotypes.
###end p 46
###begin title 47
Neurochemical analyses
###end title 47
###begin p 48
###xml 60 62 60 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
HPLC with electrochemical detection was used, as described [16], to determine the striatal concentrations of NE, dopamine, 5-HT, 3-MT, DOPAC, HVA, and 5-HIAA. Analyses were conducted without knowledge of treatment or genotype.
###end p 48
###begin title 49
Immunoblot analyses
###end title 49
###begin p 50
###xml 333 334 330 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 1796 1798 1792 1794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B71">71</xref>
###xml 31 36 <span type="species:ncbi:10090">mouse</span>
###xml 1123 1129 <span type="species:ncbi:9986">rabbit</span>
###xml 1180 1183 <span type="species:ncbi:10116">rat</span>
###xml 1348 1354 <span type="species:ncbi:9986">rabbit</span>
###xml 1391 1394 <span type="species:ncbi:10116">rat</span>
Protein lysates from dissected mouse brain tissue were prepared by sonication in a solution containing 62.5 mM Tris-HCl (pH 6.8), 2% sodium dodecyl sulfate, 2% beta-mercaptoethanol, Complete Protease Inhibitor Cocktail (Roche Diagnostics; Indianapolis, IN), and 1 mM phenylmethylsulfonyl fluoride. Samples were centrifuged (15,000 x g, 10 min) and the supernatant was used for immunoblot analysis. Protein (2 mug) was transferred to a PVDF membrane (Hybond-P; Amersham Biosciences; Piscataway, NJ) in duplicate using a slot-blot system (Bio-Rad Bio-Dot SF; Hercules, CA). A slot-blot approach was utilized because it enabled simultaneous analysis of a large number of samples and unbiased normalization using a fluorescent stain for total protein. For each sample, one replicate was subjected to immunoblot analysis, and the other replicate was analyzed for total protein using SYPRO Ruby Protein Blot stain (Molecular Probes; Eugene, OR). Membranes were blocked with 5% milk in TTBS (50 mM Tris-HCl, pH 7.5, 0.9% NaCl, 0.5% Tween20) for 1 hr, incubated with primary antibody diluted in blocking solution overnight (1:2000 rabbit anti-ubiquitin, Dako, Carpinteria, CA; or 1:10000 rat anti-DAT, Chemicon, Temecula, CA), washed 3 x 10 min in TTBS, incubated with HRP-conjugated secondary antibodies diluted in blocking solution for 1 hr (1:5000 anti-rabbit, Amersham Biosciences; 1:20000 anti-rat, Jackson ImmunoResearch Laboratories, Inc., West Grove, PA), washed 3 x 10 min in TTBS, and developed using ECL Plus (Amersham Biosciences, Piscataway, NJ). Blots were scanned using the Storm 840 system and quantitated using ImageJ (developed at the U.S. National Institutes of Health and available on the Internet at ). Oxidatively modified proteins were detected as described by Ballesteros et al. [71] using the OxyBlot Kit (Chemicon).
###end p 50
###begin title 51
Statistics
###end title 51
###begin p 52
###xml 179 184 <span type="species:ncbi:10090">mouse</span>
Data were analyzed using multi-way ANOVAs. Residuals and homogeneity of variance were evaluated to ensure the data met assumptions required for ANOVA. Data obtained from the same mouse, for instance before and after a treatment, were evaluated as a repeated measure. Data are presented as mean +/- SEM.
###end p 52
###begin title 53
Authors' contributions
###end title 53
###begin p 54
###xml 35 39 <span type="species:ncbi:10090">mice</span>
FAP developed the Parkin-deficient mice; conceived, designed, and carried out the study; analyzed and interpreted the data; and drafted the manuscript. WC performed animal surgeries and scored rotational behavior. RP participated in the design and coordination of the study. All authors read and approved the final manuscript.
###end p 54
###begin title 55
Acknowledgements
###end title 55
###begin p 56
FAP thanks the Achievement Rewards for College Scientists Foundation, Michael J. Fox Foundation, and Poncin Foundation for support. We thank Hitomi Sakano for assistance with preliminary experiments.
###end p 56
###begin article-title 57
The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living
###end article-title 57
###begin article-title 58
Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany
###end article-title 58
###begin article-title 59
A case-control study of Parkinson's disease in a horticultural region of British Columbia
###end article-title 59
###begin article-title 60
Risk factors for Parkinson's disease
###end article-title 60
###begin article-title 61
Biomedicine. Parkinson's - divergent causes, convergent mechanisms
###end article-title 61
###begin article-title 62
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
###end article-title 62
###begin article-title 63
Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1
###end article-title 63
###begin article-title 64
Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity
###end article-title 64
###begin article-title 65
Effect of wild-type or mutant Parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome
###end article-title 65
###begin article-title 66
Generation and propagation of radical reactions on proteins
###end article-title 66
###begin article-title 67
###xml 60 65 <span type="species:ncbi:9606">human</span>
Parkin is not regulated by the unfolded protein response in human neuroblastoma cells
###end article-title 67
###begin article-title 68
###xml 61 71 <span type="species:ncbi:7227">Drosophila</span>
Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants
###end article-title 68
###begin article-title 69
###xml 67 71 <span type="species:ncbi:10090">mice</span>
Mitochondrial dysfunction and oxidative damage in parkin-deficient mice
###end article-title 69
###begin article-title 70
An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage
###end article-title 70
###begin article-title 71
Degradation of misfolded proteins prevents ER-derived oxidative stress and cell death
###end article-title 71
###begin article-title 72
###xml 17 21 <span type="species:ncbi:10090">mice</span>
Parkin-deficient mice are not a robust model of parkinsonism
###end article-title 72
###begin article-title 73
###xml 17 21 <span type="species:ncbi:10090">mice</span>
Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons
###end article-title 73
###begin article-title 74
###xml 80 85 <span type="species:ncbi:10090">mouse</span>
Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse
###end article-title 74
###begin article-title 75
###xml 67 71 <span type="species:ncbi:10090">mice</span>
Loss of locus coeruleus neurons and reduced startle in parkin null mice
###end article-title 75
###begin article-title 76
###xml 50 58 <span type="species:ncbi:9606">patients</span>
Expanding phenotype and clinical heterogeneity in patients with identical mutation of the parkin gene
###end article-title 76
###begin article-title 77
How much phenotypic variation can be attributed to parkin genotype?
###end article-title 77
###begin article-title 78
Marked variation in clinical presentation and age of onset in a family with a heterozygous parkin mutation
###end article-title 78
###begin article-title 79
Parkin: a multipurpose neuroprotective agent?
###end article-title 79
###begin article-title 80
Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons
###end article-title 80
###begin article-title 81
The role of oxidative stress, impaired glycolysis and mitochondrial respiratory redox failure in the cytotoxic effects of 6-hydroxydopamine in vitro
###end article-title 81
###begin article-title 82
Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease
###end article-title 82
###begin article-title 83
Parkinsonian mimetics induce aspects of unfolded protein response in death of dopaminergic neurons
###end article-title 83
###begin article-title 84
6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson's disease
###end article-title 84
###begin article-title 85
6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation
###end article-title 85
###begin article-title 86
The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons
###end article-title 86
###begin article-title 87
###xml 16 21 <span type="species:ncbi:9606">human</span>
Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis
###end article-title 87
###begin article-title 88
Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport
###end article-title 88
###begin article-title 89
Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine
###end article-title 89
###begin article-title 90
###xml 39 42 <span type="species:ncbi:10116">rat</span>
Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate: impact of methamphetamine
###end article-title 90
###begin article-title 91
###xml 69 74 <span type="species:ncbi:10090">mouse</span>
Parallel increases in lipid and protein oxidative markers in several mouse brain regions after methamphetamine treatment
###end article-title 91
###begin article-title 92
###xml 57 60 <span type="species:ncbi:10116">rat</span>
Formation of 6-hydroxydopamine in caudate nucleus of the rat brain after a single large dose of methylamphetamine
###end article-title 92
###begin article-title 93
Rapid and transient inhibition of mitochondrial function following methamphetamine or 3,4-methylenedioxymethamphetamine administration
###end article-title 93
###begin article-title 94
###xml 48 53 <span type="species:ncbi:10090">mouse</span>
Rapid ATP loss caused by methamphetamine in the mouse striatum: relationship between energy impairment and dopaminergic neurotoxicity
###end article-title 94
###begin article-title 95
Substrates of energy metabolism attenuate methamphetamine-induced neurotoxicity in striatum
###end article-title 95
###begin article-title 96
Central administration of methamphetamine synergizes with metabolic inhibition to deplete striatal monoamines
###end article-title 96
###begin article-title 97
Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis
###end article-title 97
###begin article-title 98
Methamphetamine produces neuronal inclusions in the nigrostriatal system and in PC12 cells
###end article-title 98
###begin article-title 99
Methamphetamine induces neuronal apoptosis via cross-talks between endoplasmic reticulum and mitochondria-dependent death cascades
###end article-title 99
###begin article-title 100
Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine
###end article-title 100
###begin article-title 101
High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity
###end article-title 101
###begin article-title 102
Protein oxidation in aging, disease, and oxidative stress
###end article-title 102
###begin article-title 103
A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease
###end article-title 103
###begin article-title 104
Free 3-nitrotyrosine causes striatal neurodegeneration in vivo
###end article-title 104
###begin article-title 105
Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae
###end article-title 105
###begin article-title 106
The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments
###end article-title 106
###begin article-title 107
Further studies of the role of hyperthermia in methamphetamine neurotoxicity
###end article-title 107
###begin article-title 108
Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases
###end article-title 108
###begin article-title 109
###xml 30 33 <span type="species:ncbi:10116">rat</span>
###xml 38 43 <span type="species:ncbi:9606">human</span>
Parkin transcript variants in rat and human brain
###end article-title 109
###begin article-title 110
###xml 36 41 <span type="species:ncbi:10090">mouse</span>
Parkin expression in the developing mouse
###end article-title 110
###begin article-title 111
Pathogenic mutations inactivate parkin by distinct mechanisms
###end article-title 111
###begin article-title 112
Parkin binds the Rpn10 subunit of 26 S proteasomes through its ubiquitin-like domain
###end article-title 112
###begin article-title 113
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
###end article-title 113
###begin article-title 114
Gene targeting: technical confounds and potential solutions in behavioral brain research
###end article-title 114
###begin article-title 115
Congenic Strains
###end article-title 115
###begin article-title 116
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse Genome Informatics
###end article-title 116
###begin article-title 117
###xml 60 64 <span type="species:ncbi:10090">mice</span>
Spontaneous hypomorphic mutations in antioxidant enzymes of mice
###end article-title 117
###begin article-title 118
###xml 116 120 <span type="species:ncbi:10090">mice</span>
Tissue-specific developmental regulation of superoxide dismutase (SOD-1 and SOD-2) activities in genetic strains of mice
###end article-title 118
###begin article-title 119
Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death
###end article-title 119
###begin article-title 120
Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity
###end article-title 120
###begin article-title 121
###xml 100 103 <span type="species:ncbi:10116">rat</span>
Effect of the neurotoxic dose of methamphetamine on gene expression of parkin and Pael-receptors in rat striatum
###end article-title 121
###begin article-title 122
Role of tumor necrosis factor-alpha in methamphetamine-induced drug dependence and neurotoxicity
###end article-title 122
###begin article-title 123
Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death
###end article-title 123
###begin article-title 124
A role for dopamine in feeding responses produced by orexigenic agents
###end article-title 124
###begin article-title 125
Viral restoration of dopamine to the nucleus accumbens is sufficient to induce a locomotor response to amphetamine
###end article-title 125
###begin article-title 126
Bacterial senescence: protein oxidation in non-proliferating cells is dictated by the accuracy of the ribosomes
###end article-title 126
###begin title 127
Figures and Tables
###end title 127
###begin p 128
###xml 0 65 0 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Parkin deficient-mice are not more sensitive to 6-OHDA toxicity. </bold>
###xml 65 68 65 68 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A. </bold>
###xml 292 295 290 293 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B. </bold>
###xml 441 444 439 442 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C. </bold>
###xml 17 21 <span type="species:ncbi:10090">mice</span>
###xml 68 70 <span type="species:ncbi:10090">WT</span>
###xml 71 75 <span type="species:ncbi:10090">mice</span>
###xml 104 106 <span type="species:ncbi:10090">KO</span>
###xml 107 111 <span type="species:ncbi:10090">mice</span>
###xml 425 427 <span type="species:ncbi:10090">WT</span>
###xml 432 434 <span type="species:ncbi:10090">KO</span>
###xml 435 439 <span type="species:ncbi:10090">mice</span>
###xml 476 478 <span type="species:ncbi:10090">WT</span>
###xml 483 485 <span type="species:ncbi:10090">KO</span>
###xml 486 490 <span type="species:ncbi:10090">mice</span>
###xml 664 668 <span type="species:ncbi:10090">mice</span>
###xml 723 727 <span type="species:ncbi:10090">mice</span>
Parkin deficient-mice are not more sensitive to 6-OHDA toxicity. A. WT mice (filled square symbols) and KO mice (open circle symbols) treated with 4 mug 6-OHDA or 8 mug 6-OHDA displayed similar contralateral, rotational behavior (expressed as net negative rotations) following APO-treatment. B. Ipsilateral rotational behavior (expressed as net positive rotations) following AMPH treatment was also indistinguishable between WT and KO mice. C. There was no difference between WT and KO mice in striatal dopamine (DA) levels (expressed as ng/mg protein) on the intact, uninjected side versus the side treated with SAL, 4 mug 6-OHDA, or 8 mug 6-OHDA. The numbers of mice used for each genotype are indicated in A; these same mice were also analyzed in B and C. Data are expressed as mean +/- SEM.
###end p 128
###begin p 129
###xml 0 63 0 63 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Parkin-deficient mice are not more sensitive to METH toxicity. </bold>
###xml 110 113 110 113 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A. </bold>
###xml 127 130 127 130 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B. </bold>
###xml 336 339 330 333 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C. </bold>
###xml 491 494 485 488 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D. </bold>
###xml 17 21 <span type="species:ncbi:10090">mice</span>
###xml 170 172 <span type="species:ncbi:10090">WT</span>
###xml 201 203 <span type="species:ncbi:10090">KO</span>
###xml 226 230 <span type="species:ncbi:10090">mice</span>
###xml 371 373 <span type="species:ncbi:10090">WT</span>
###xml 378 380 <span type="species:ncbi:10090">KO</span>
###xml 381 385 <span type="species:ncbi:10090">mice</span>
###xml 650 652 <span type="species:ncbi:10090">WT</span>
###xml 677 681 <span type="species:ncbi:10090">mice</span>
Parkin-deficient mice are not more sensitive to METH toxicity. The hyperthermic response to METH treatment at A. 2.5 mg/kg and B. 5.0 mg/kg was indistinguishable between WT (filled square symbols) and KO (open circle symbols) mice. Body temperature (degreesC) was measured before METH treatment (time = 0 hr) and every hour thereafter. C. There was no difference between WT and KO mice in the depletion of striatal dopamine (DA) levels (expressed as ng/mg protein) following METH treatment. D. There was also no difference in the reduction of striatal DAT levels following METH treatment (data are expressed in arbitrary units after normalization to WT levels). The numbers of mice used for each genotype are indicated in the figure. Data are expressed as mean +/- SEM.
###end p 129
###begin p 130
###xml 45 50 <span type="species:ncbi:10090">mouse</span>
###xml 136 138 <span type="species:ncbi:10090">WT</span>
Immunoblot analyses of aged Parkin-deficient mouse brains. Data are expressed as mean +/- SEM in arbitrary units after normalization to WT levels.
###end p 130

